News brief.
Business leaders not infrequently give speeches saying that they are concerned with the overall health of the community. But how often do they devote corporate energies to programs that do not directly affect their own employees? The Colorado Health and Hospital Association is actively trying to get local employers to do exactly that in order to raise Medicaid reimbursements.
The group calculates that Colorado hospitals lost $45 million on Medicaid patients in 1999. Now the state is proposing a $21.7 million cut in the program, on top of a cut of around $5 million last year. "It's critically important for the business community to understand that if [Medicaid] payments are short, costs are being shifted to them," association President Larry Wall argues. "This really is a hidden tax on business."
The hospital group thus far has persuaded business publications in the state to do articles about the Medicaid crisis and goaded the Denver Chamber of Commerce into appointing a task force to recommend Medicaid restructuring. Most significantly, the board of the Colorado Association of Commerce and Industry adopted a resolution backing the hospitals' campaign against further Medicaid budget cuts. The statewide group hasn't put the issue on its own lobbying agenda, but it is writing its members and encouraging them to contact their state lawmakers. "Those two steps will certainly help us," Wall insists, "but the jury is still out."
Daniel Moskowitz. Colorado hospitals emphasize business stake in Medicaid.
Business and Health
2001;4:18.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More